Recurrent Gliosarcoma
15
5
9
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
6.7%
1 terminated out of 15 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme